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Problem Identification


Prostate cancer is the most commonly diagnosed cancer in men (119.8 per 100,000) and had the 2nd
highest mortality (20.1 per 100,000)1


VT mortality is higher than the national average (21.1 per 100,000)



About 1 in 9 men will be diagnosed with prostate cancer in their life1



25% of cancers diagnosed in VT males prostate cancer2



10% of cancer mortality in VT males is due to prostate cancer2



Vermont Cancer Plan 2020 Goal 11.1: “Increase % of primary care providers who conduct prostate
cancer risk assessment with their adult male patients age 50-70”



Recurrent guideline changes may lead to confusion among both providers and about what screening
is recommended


The USPSTF is planning on changing the screening guidelines to make screening for prostate cancer in men aged
55-70 years category C, recommending patient and provider discussion, and category D for men >70 years old
2

Cost Considerations


In 20063


Total U.S. expenditure on prostate cancer:
$9.862 billion







$10,612 initially after diagnosis



$2,134 for continuing care



$33,691 for last year of life

In 20104




Mean annual cost per patient:

Total expenditure rose to $11.85 billion

Estimates of the national expenditures for cancer care in
2010 (light gray areas) and estimated increase in cost in
2020 (dark gray areas) because of aging and growth of the
US population under assumptions of constant incidence
survival and cost for the major cancer sites. Costs in 2010
billion US dollars by phase of care: initial year after
diagnosis (Ini.) continuing care (Con.) and last year of life
(Last).4

By 2020


Costs for prostate cancer are expected to rise by as much as 42%
3

Community Perspective


Marie Claude Bennencourt, MD, a urologist in Springfield, VT estimates that
since the USPSTF recommended against routine PSA screening in 2012 she has
seen an increase in diagnosing later stage prostate cancer, including
metastatic disease.




She recognized that urology does not use USPSTF guidelines but that it appears to
have influenced many providers given her conversation with primary care providers
and the number of patients without PSA screening on first visit

Patients at Springfield Family Practice Associates say that they would follow
their doctors recommendations about testing but would have much greater
confidence with the USPSTF guidelines backing their provider


Patients also say they do not know much about prostate cancer besides what their
primary care provider tells them
4

Proposed intervention




Provide patient education about


Current screening guidelines



Information about prostate cancer and what to expect with screening



Introduction to the risks and benefits of screening and the follow-up

This information will hopefully allow patients to be better prepared for a
discussion with their provider about prostate cancer OR allow the patient to
initiate the discussion with the provider


This should result in increased discussions about screening allowing for better
informed patients and more goal-oriented care

5

Results


The result is a tri-fold pamphlet which can be provided to the patients by the
provider at the time of the discussion or placed in the waiting room for
patients to pick up at their will


This brochure can be used by the provider as patient education at the time of
initiation of screening
OR



Can be used by the patient to gain knowledge about prostate cancer before
starting the conversation with the provider themselves
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Evaluation of Effectiveness/Limitations
Effectiveness:


Physicians appear eager to have more clarity and information regarding PSA
screening



In particular they seem interested in having information to provide to patients



Many patients seem interested in learning more about screening and are
interested in discussing screening with their PCP

Limitations:


Providers need to be reminded to have the conversation with patients



There is still some uncertainty about the efficacy of PSA screening



Some providers have individual feelings about whether or not they want to
complete PSA screening, this might lead to conflict with their patient population



Patients must be willing and interested in reading the brochure and engage in
discussion with providers; its efficacy is not yet proven
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Recommendations for Future
Interventions


Evaluation of the efficacy of providing patient information by tracking:


The amount that providers utilize brochure to help educate patients



The number of discussions initiated by patients



Create a Dot phrase and/or EMR tool to remind providers to initiate screening
discussion in appropriately aged male patients and track which patients still need
to have the discussion



Ultimately, the goal of the pamphlet is to encourage discussion so:


Tracking the percentage of encounters in which the risks and benefits of PSA screening
are discussed



Following the number of PSA tests conducted
8
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